The prognosis and natural history of primary biliary cirrhosis (PBC) have improved significantly during the last few decades. Patients are diagnosed at earlier stages, are more likely to be ...

September is the perfect time to turn up the volume on conversations about Primary Biliary Cholangitis (PBC) and the symptoms people living with it experience, in support of PBC Awareness Month.

This investigation of 23 patients with the clinical syndrome of "primary biliary cirrhosis" was undertaken to elucidate the morphologic nature of the hepatic alterations, including their etiology ...

Primary billiary cholangitis, or PBC, is a chronic disease that gradually damages the bile ducts, and eventually your liver. You may also hear it called primary billiary cirrhosis. Your bile ducts ...

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade. With the FDA approval of Gilead's ...

Primary biliary cirrhosis (PBC) is a chronic, cholestatic liver disease characterized by progressive destruction of intrahepatic bile ducts, resulting in chronic cholestasis, portal inflammation ...

A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments. Learn the critical warning signs of Primary biliary cholangitis (PBC) and ...

Livdelzi (seladelpar) is a medicine that can treat primary biliary cholangitis (PBC) by reducing the amount of bile in your body. It does this by signaling the body to stop making bile acid.

These quiz questions about primary biliary cholangitis (PBC) are derived from current literature. Are you up to date? At the end of the quiz, compare your score with those of your physician ...

Primary biliary cholangitis (PBC) can deliver a significant blow to patients' quality of life, especially if they are not appropriately diagnosed and treated. "PBC is one of those liver diseases ...

Recently, we added a treatment to our portfolio, which has the potential to be impactful for people living with primary biliary cholangitis (PBC). PBC is a rare liver disease that affects about ...

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...